Objective: To explore the development of a CAR-T cells targeting CLL-1 and verify its function. Methods: The expression levels of CLL-1 targets in cell lines and primary cells were detected by flow cytometry. A CLL-1 CAR vector was constructed, and the corresponding lentivirus was prepared. After infection and activation of T cells, CAR-T cells targeting CLL-1 were produced and their function was verified in vitro and in vivo. Results: CLL-1 was expressed in acute myeloid leukemia (AML) cell lines and primary AML cells. The transduction rate of the prepared CAR T cells was 77.82%. In AML cell lines and AML primary cells, CLL-1-targeting CAR-T cells significantly and specifically killed CLL-1-expressing cells. Compared to untransduced T cells, CAR-T cells killed target cells and secreted inflammatory cytokines, such as interleukin-6 and interferon-γ, at significantly higher levels (P<0.001) . In an in vivo human xenograft mouse model of AML, CLL-1 CAR-T cells also exhibited potent antileukemic activity and induced prolonged mouse survival compared with untransduced T cells [not reached vs 22 days (95%CI 19-24 days) , P=0.002]. Conclusion: CAR-T cells targeting CLL-1 have been successfully produced and have excellent functions.
目的： 探索开发一种靶向CLL-1的嵌合抗原受体T细胞（CAR-T细胞）并验证其功能。 方法： 通过流式细胞术检测急性髓系白血病（AML）细胞系和AML原代细胞CLL-1靶点的表达水平。构建CLL-1 CAR载体并制备出相应慢病毒，感染激活后T细胞生产出CAR-T细胞，并通过体外和体内实验验证CLL-1 CAR-T细胞的功能。 结果： AML细胞系和原代AML细胞中均表达CLL-1。制备的CLL-1 CAR-T细胞转导率为77.82%，在AML细胞系以及AML原代细胞中，CLL-1 CAR-T细胞能明显特异性杀伤表达CLL-1的靶细胞系和原代肿瘤细胞。相对于未转导的T细胞，CLL-1 CAR-T细胞在杀伤靶细胞和原代肿瘤细胞时分泌IL-6、IFN-γ等细胞因子水平更高（P值均<0.001）。在AML人源性异种移植小鼠模型中，相对于未转导的T细胞，CLL-1 CAR-T细胞表现出有效的抗白血病活性并延长小鼠存活时间[未达到对22（95%CI 19~24）d，P=0.002]。 结论： 靶向CLL-1的CAR-T细胞成功开发并具有较好的肿瘤杀伤作用。.
Keywords: C-type lectin-like molecule 1; Cell therapy; Chimeric antigen receptor; Leukemia, myeloid, acute.